Your session is about to expire
← Back to Search
SMArTVIEW for Post-Cardiac Surgery Monitoring (SMArTVIEW Trial)
N/A
Waitlist Available
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥ 60 years;
Patient has undergone major cardiac or vascular surgery and has been admitted post-op to the surgical floor;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion. an average of 1 year.
Awards & highlights
No Placebo-Only Group
Summary
This trial evaluates the SMArTVIEW program, which uses remote monitoring technology to help patients who have had heart or major blood vessel surgery. The program checks vital signs continuously and provides nurse support through video calls, aiming to reduce hospital readmissions and emergency visits.
Who is the study for?
This trial is for individuals aged 60 or older who have had major cardiac or vascular surgery and are expected to stay in the hospital for at least 48 hours post-op. They must be mentally clear (as shown by a negative CAM test) and able to consent on their own.
What is being tested?
The SMArTVIEW program is being tested, which involves remote, automated monitoring of patients after cardiac or vascular surgery. The goal is to see if it reduces hospital readmissions and emergency visits within 45 days post-surgery compared to standard care.
What are the potential side effects?
Since SMArTVIEW is a monitoring intervention rather than a medication, traditional side effects like those seen with drugs are not applicable. However, there may be issues related to privacy concerns or discomfort with technology use.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 60 years old or older.
Select...
I had major heart or blood vessel surgery and was admitted to the hospital afterwards.
Select...
I expect to stay in the hospital for surgery for at least 2 days.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion. an average of 1 year.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion. an average of 1 year.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Hospital Readmission Rate
Secondary study objectives
Composite of Major Complications associated with Undetected Hemodynamic Compromise
Econometrics
Process & Implementation
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: SMArTVIEWExperimental Treatment1 Intervention
Group II: Standard CareActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SMArTVIEW
2018
N/A
~580
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for cardiac surgery patients include atrial pacing, placement of pericardial drains, and the use of medications like colchicine to prevent pericarditis. Atrial pacing helps maintain a regular heart rhythm, reducing the risk of postoperative atrial fibrillation.
Pericardial drains prevent fluid accumulation around the heart, which can trigger arrhythmias. Colchicine reduces inflammation, further lowering the risk of complications.
Remote and automated monitoring, as studied in the SMArTVIEW trial, allows for continuous assessment of a patient's condition, enabling early detection and intervention for complications such as arrhythmias or fluid buildup. This proactive approach is crucial for improving outcomes and reducing readmissions and urgent care visits in cardiac surgery patients.
Management of cardiogenic shock.Improving Care Using a Bidirectional Geriatric Cardiology Consultative Conference.Surgical options for the management of ischemic cardiomyopathy.
Management of cardiogenic shock.Improving Care Using a Bidirectional Geriatric Cardiology Consultative Conference.Surgical options for the management of ischemic cardiomyopathy.
Find a Location
Who is running the clinical trial?
Population Health Research InstituteOTHER
164 Previous Clinical Trials
717,942 Total Patients Enrolled
McMaster UniversityLead Sponsor
917 Previous Clinical Trials
2,615,681 Total Patients Enrolled
Ontario Centres of ExcellenceIndustry Sponsor
4 Previous Clinical Trials
365 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,392 Previous Clinical Trials
26,528,873 Total Patients Enrolled